RESUMO
The occurrence of foam in a lowland river in Austria and shortly after the border with Hungary and the consequent protests from Hungarian inhabitants led to investigations concerning the reasons for foam formation. The aims of the study were (i) to specify objectively the scale of appearing of foam, (ii) to evaluate reasons for foam formation, and (iii) to develop abatement measures.
Assuntos
Rios/química , Purificação da Água/métodos , Abastecimento de Água/análise , Áustria , Hungria , Modelos Químicos , Ozônio/química , Análise de Regressão , Reprodutibilidade dos TestesRESUMO
In the context of an investigative monitoring programme a monitoring system comprising of a water quality monitoring station and a camera station has been installed and operated for more than one year. The monitoring target was to investigate changes of water quality which can be related to a repeated occurrence of foam, observed at a river stretch downstream the monitoring station. The extent and frequency of foam buildup was recorded by means of the camera station. The analysis of the online data clearly showed that some of the measured parameters can be used as indicators for specific discharges, which from additional targeted investigations could be identified as contributors to the foaming problems. The continuous ammonium measurement could be used to detect nitrification problems of WWTPs discharging upstream of the monitoring station. By combining different data sources (emission data, operative and investigative monitoring data) additional information can be gained, which can be used for a comprehensive data assessment as well as a detailed system analysis.
Assuntos
Monitoramento Ambiental , Atividades Humanas , Rios/química , Difusão , Indústrias , Nitratos/análise , Compostos de Amônio Quaternário/análise , Fatores de TempoRESUMO
Cyclosporine is a widely used and potent immunosuppressant drug with a narrow therapeutic index. Therefore, cyclosporine concentrations should be monitored closely. Various automated immunologic methods for cyclosporine whole blood determinations are available. Two new methods, fluorescence polarization immunoassay (FPIA) for the AxSYM by Abbott Laboratories, Chicago, IL, and the cloned enzyme donor immunoassay (CEDIA) by Boehringer Mannheim, Mannheim, Germany, have been introduced. In addition, Dade Behring improved its enzyme multiplied immunoassay (EMIT) assay. The present study evaluated all 3 new methods in comparison with high-performance liquid chromatography (HPLC) and the FPIA for the TDx analyzer. We measured whole blood cyclosporine concentrations of 179 samples obtained from 127 patients after kidney, bone marrow, heart-lung, and liver transplantation. All 4 automated immunologic methods can be used for routine measurement of cyclosporine whole blood concentrations. Disadvantages, such as higher cross-reactivity (Abbott TDx, CEDIA) or a limited linearity range (EMIT), are accompanied by advantages, such as a high precision (Abbott TDx) or an easy sample handling procedure (CEDIA). Information presented in this article should help to find the most adequate cyclosporine method for each medical laboratory.
Assuntos
Autoanálise/métodos , Ciclosporina/sangue , Imunossupressores/sangue , Anticorpos Monoclonais , Transplante de Medula Óssea , Cromatografia Líquida de Alta Pressão , Estudos de Avaliação como Assunto , Transplante de Coração , Humanos , Imunoensaio , Transplante de Rim , Modelos Lineares , Transplante de Fígado , Reprodutibilidade dos TestesRESUMO
In the present study the coagulation analyzer SYSMEX CA 6000 (TOA Medical Electronics Co., Kobe, Japan), an analyzer equipped with a photooptical clot detection unit and a cap-piercing system, was evaluated with respect to its technical characteristics in the determination of standard coagulation tests (prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, and antithrombin) and in the determination of coagulation single factor activities. In the normal and in the pathological range the intraassay coefficients of variation (CV) and interassay CV for most parameters were below 5% (exceptions: intraassay CV 5.4% for prolonged thrombin time; intraassay CV 9.26% and interassay CV 10.7% for decreased antithrombin; interassay CV 5.62% for fibrinogen in the normal range, intraassay CV 10.1% for fibrinogen greater than 7.0 g/L; intraassay CV 6.36% and interassay CV 11.7% for decreased fibrinogen; interassay CV 11.6% for prolonged activated partial thromboplastin time; interassay CV 6.12% for decreased factor VII). Interference studies with lipemic, icteric, and hemolytic samples showed just minor influences of these abnormal sample characteristics on prothrombin time, activated partial thromboplastin time, fibrinogen, and antithrombin measurements when compared to the results obtained by using mechanical clot detection (STA, Stago Diagnostica, Asnieres-Sur-Seine, France). No carryover was detected in alternating measurements of heparinized (3 U/mL unfractionated heparin) and normal plasma samples. Measurement of the activities of clotting factors V, VII, VIII, and IX showed a good correlation (r=0.993 to r=0.977) between SYSMEX CA 6000 and STA. Our results demonstrate that using SYSMEX CA 6000 analyzer basal routine coagulation testing as well as specialized tests for single factor activities can be performed with satisfactory precision; in particular, the cap-piercing system has no negative effect on the performance of the analyzer.
Assuntos
Testes de Coagulação Sanguínea/instrumentação , Adulto , Antitrombinas/análise , Compostos Cromogênicos , Feminino , Fibrinogênio/análise , Humanos , Masculino , Pessoa de Meia-Idade , Tempo de Tromboplastina Parcial , Tempo de Protrombina , Análise de Regressão , Tempo de TrombinaRESUMO
Coagulation factor XII (FXII) deficiency is rarely found to be associated with bleeding, but single reports demonstrated thromboembolic events in FXII-deficient patients. Currently, the biological role of FXII is still discussed controversially. It is well known that plasma levels of FXII show great interindividual variability. Recently, it has been demonstrated that a frequently occurring C-->T polymorphism in the FXII promoter region at nucleotide (nt) 46 is associated with lower plasma FXII activity levels in Orientals. In our study, we evaluated the frequency of this polymorphism in a randomly selected sample of newborns and investigated whether this C-->T polymorphism also contributes to the frequently observed moderate FXII deficiency in Europeans. We developed a new mutagenically separated polymerase chain reaction assay (MS PCR), which allows mutation detection without the use of restriction enzymes. Among 100 healthy newborns, we found 64% homozygous carriers of the wildtype FXII 46C allele, 29% were heterozygous for FXII C46T, and 7% homozygous for FXII 46T. Evaluation of plasma FXII activity and genotype in 80 randomly selected and unrelated individuals revealed a highly statistically significant (P<.001) association of the FXII 46T allele with reduced FXII plasma activity. Individuals carrying the homozygous FXII 46C genotype had a mean of 1.17 U/ml (+/-0.31 U/ml), individuals heterozygous for FXII C46T showed a mean of 0.70 U/ml (+/-0.31 U/ml), and subjects homozygous for FXII 46T had only 0.44 U/ml (+/-0.10 U/ml) plasma FXII activity.
Assuntos
Deficiência do Fator XII/sangue , Deficiência do Fator XII/genética , Fator XII/genética , Fator XII/metabolismo , Polimorfismo Genético , Regiões Promotoras Genéticas , Alelos , Áustria , Sequência de Bases , Análise Mutacional de DNA/métodos , Primers do DNA/genética , Feminino , Frequência do Gene , Genótipo , Heterozigoto , Humanos , Recém-Nascido , Masculino , Fenótipo , Reação em Cadeia da Polimerase/métodosRESUMO
In the present study a new assay, ProC Global, globally estimating the activity of the main plasma components of anticoagulant protein C/protein S pathway, was evaluated with respect to test characteristics and its sensitivity in the detection of deficiency states of protein C and protein S and of increased aPCR. In the ProC Global assay procedure protein C is activated in patient's plasma by an activator reagent (venom from agkistrodon contortrix). The extent of the prolongation of a sample's aPTT, caused by the activation of protein C, is taken as a measure for its anticoagulant capacity. Ninety-eight patients with one of the above mentioned defects were investigated. Decreased plasma protein C activity and increased aPCR were detected with a sensitivity of 1.0, while only 11 of 14 patients with decreased levels of free protein S antigen showed abnormal results in the ProC Global assay (sensitivity = 0.79). The test can be used in heparinized samples up to 1.0 anti Xa U/ml heparin (UFH and LMWH). When samples from patients on oral anticoagulant treatment are prediluted with factor V deficient plasma the test is sensitive for increased aPCR.
Assuntos
Anticoagulantes/metabolismo , Testes de Coagulação Sanguínea/métodos , Coagulação Sanguínea/fisiologia , Proteína C/metabolismo , Proteína S/metabolismo , Administração Oral , Adulto , Anticoagulantes/administração & dosagem , Anticoagulantes/farmacologia , Transtornos da Coagulação Sanguínea/sangue , Transtornos da Coagulação Sanguínea/fisiopatologia , Estudos de Avaliação como Assunto , Feminino , Heparina/farmacologia , Humanos , Inibidor de Coagulação do Lúpus/farmacologia , Masculino , Pessoa de Meia-Idade , Tempo de Tromboplastina Parcial , Proteína C/efeitos dos fármacos , Deficiência de Proteína C , Proteína S/efeitos dos fármacos , Deficiência de Proteína S/diagnóstico , Tempo de Protrombina , Sensibilidade e Especificidade , TemperaturaRESUMO
In the present study CoaguCheck Plus (CCP), a coagulation test system using whole blood, was evaluated with respect to its comparability with widely distributed conventional routine coagulation assays. A correlation of r = 0.997 (p < 0.0001) was found between INR of CCP-prothrombin time (CCP-PT) and Thrombotest (KC-1 analyzer) in patients on oral anticoagulant therapy. A correlation of r = 0.899 (p < 0.001) between CCP-aPTT and Actin ES aPTT (STA analyzer) was found in heparinized patients. Impaired hepatic hepatic coagulation factor synthesis in liver cirrhosis patients was detected by CCP-PT with a sensitivity of 0.75 and by Normotest (STA analyzer) with a sensitivity of 0.92. Those patients with normal CCP-PT values and liver disease had, only mild reductions (> 30% of normals) in coagulation factors II, V, VII or X. CCP-aPTT was also performed in patients with a deficiency in the so called endogenous coagulation factors VIII, IX, XI and XII. CCP-aPTT showed a sensitivity similar to that of Actin FS aPTT in the detection even of mild deficiencies in factors VIII, IX and XII; factor XI deficiency was however detected only in patients with severe (< 12% of normals) disease; lupus anticoagulants were detected with a high sensitivity.
Assuntos
Testes de Coagulação Sanguínea/instrumentação , Tempo de Protrombina , Heparina/uso terapêutico , Humanos , Indicadores e Reagentes , Testes de Função Hepática , Inibidor de Coagulação do Lúpus/análise , Tempo de Tromboplastina Parcial , Sistemas Automatizados de Assistência Junto ao Leito , Valores de Referência , Sensibilidade e EspecificidadeRESUMO
In the present study the formation of thrombin-antithrombin-complexes (TAT) during incubation of thrombin (0.89, 4.5, 8.9 nmol/l) and antithrombin (4.6 micromol/l) on the surface of cultured human EC, derived from different parts of the circulation, and on the surface of human vessel segments was studied. In the absence of EC TAT increased over time reaching a maximum at 60 sec; 10 sec (8.9 nmol/l thrombin): 6.35+/-0.72 nmol/l, 60 sec: 10.49+/-1.04 nmol/l. In the presence of exogenous heparin (0.1 IU/ml) maximum TAT levels were already reached after 10 sec (10.75+/-0.97); cultured EC and EC on vessel segments did not show such heparin effects. Incubation of EC with heparin resulted in an EC-surface localized heparin activity only when very high doses (3.0 IU/ml) of the drug were used. When thrombin was incubated on the EC surface in the presence of AT the efficiency of the thrombomodulin(TM)-protein C(PC)-system was markedly reduced, while in the presence of exogenous heparin (0.5 IU/l) the activity of this pathway was nearly abolished. Our results demonstrate that 1) human EC do not exert heparin-like accelerating effects on TAT formation, 2) an EC localized heparin activity is only generated when EC are incubated with amounts clearly exceeding therapeutical doses, and 3) an acceleration of TAT formation at the EC surface by heparin causes a switching off of the TM-PC-system.
Assuntos
Anticoagulantes/metabolismo , Antitrombinas/metabolismo , Endotélio Vascular/metabolismo , Hemostáticos/metabolismo , Heparina/metabolismo , Trombina/metabolismo , Anticoagulantes/farmacologia , Aorta/citologia , Aorta/efeitos dos fármacos , Aorta/metabolismo , Coagulação Sanguínea/fisiologia , Células Cultivadas , Endotélio Vascular/citologia , Endotélio Vascular/efeitos dos fármacos , Feminino , Heparina/farmacologia , Humanos , Ligação Proteica , Proteína C/metabolismo , Trombomodulina/metabolismo , Veias Cavas/citologia , Veias Cavas/efeitos dos fármacos , Veias Cavas/metabolismoRESUMO
CONTEXT: The new hematology analyzer Sysmex XE-2100 (TOA Medical Electronics, Kobe, Japan) has a novel, combined, white blood cell differential technology and a special reagent system to enumerate nucleated red blood cells. DESIGN: Performance evaluation of both technologies of the Sysmex XE-2100 according to the H20-A protocol of the National Committee for Clinical and Laboratory Standards and comparison of the results with those for the hematology analyzer Sysmex NE-8000 (TOA Medical Electronics). SPECIMENS: Five hundred forty-four blood samples randomly chosen from various inpatient and outpatient departments of the Vienna University hospital. RESULTS: Five-part white blood cell differential counts on the XE-2100 revealed excellent correlation with the manual reference method for neutrophils, lymphocytes, and eosinophils (r =.925,.922, and.877, respectively) and good correlation for monocytes and basophils (r =.756 and.763, respectively). The efficiency rates of flagging for the presence of >/=1% abnormal white blood cells were 83% (XE-2100) and 66% (NE-8000). The correlation of automated and microscopic nucleated red blood cell counts was excellent (r =.97). CONCLUSIONS: From the present evaluation and our former experience with other types of Sysmex analyzers, we conclude that the new white blood cell differential technology of the XE-2100 represents a further development toward more efficient flagging of abnormal white blood cells.
Assuntos
Autoanálise/normas , Hematologia/instrumentação , Contagem de Leucócitos/normas , Eritroblastos/citologia , Contagem de Eritrócitos/instrumentação , Reações Falso-Negativas , Reações Falso-Positivas , Hematologia/normas , Humanos , Contagem de Leucócitos/instrumentação , Leucócitos/patologia , Sensibilidade e EspecificidadeRESUMO
BACKGROUND: Diurnal fluctuations of blood coagulation and fibrinolysis activity are thought to play a role in the observed circadian variation in the frequency of onset of acute cardiovascular events. In the present study, the diurnal variations in blood coagulation and fibrinolysis activity were investigated in 10 young, healthy control subjects by use of specific molecular activation markers. METHODS AND RESULTS: The plasma levels of activated factor FVII (FVIIa), the active portion of the main coagulation activator, decreased during the day (8 AM: 2.03 ng/mL, CI 1.16 to 2.88 ng/mL; 8 PM: 1.16 ng/mL, CI 0.81 to 1.5 ng/mL; P = .005), whereas FVII antigen did not change significantly. In parallel with the diurnal variations of FVIIa, we found a decrease of prothrombin fragment F1+2 (8 AM: 0.97 nmol/L, CI 0.79 to 1.15 nmol/L; 8 PM: 0.78 nmol/L, CI 0.64 to 0.93 nmol/L; P = .005), a molecular marker of intravasal thrombin generation. Evidence for a possible functional relevance of circulating FVIIa was found because this parameter was significantly correlated with prothrombin fragment F1+2 in 72 fasting healthy individuals (r = .29, P = .011). Plasminogen activator inhibitor-1 levels decreased (8 AM: 9.9 ng/mL, CI 7.7 to 12.1 ng/mL; 8 PM: 5.4 ng/mL, CI 3.8 to 6.9 ng/mL; P < .005), whereas plasmin-plasmin inhibitor complex levels, representing the degree of intravascular plasmin generation, concomitantly increased (8 AM: 235 micrograms/L, CI 198 to 272 micrograms/L; 8 PM: 449 micrograms/L, CI 391 to 507 micrograms/L; P = .008). CONCLUSIONS: Our data suggest that the diurnal changes in the plasma levels of activators and inhibitors of coagulation and fibrinolysis lead to corresponding changes in the activity state of these systems, leading to morning hypercoagulability and hypofibrinolysis.